14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Tuesday, 7th May 2024 MGNX stock ended at $16.05. This is 1.95% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 4.80% from a day low at $15.62 to a day high of $16.37.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical MacroGenics prices

Date Open High Low Close Volume
Nov 22, 2016 $27.50 $27.77 $26.43 $27.18 206 881
Nov 21, 2016 $28.09 $28.39 $27.16 $27.48 237 440
Nov 18, 2016 $29.13 $29.45 $28.02 $28.15 167 464
Nov 17, 2016 $29.16 $29.48 $28.40 $28.92 254 672
Nov 16, 2016 $31.00 $31.10 $28.96 $29.00 205 732
Nov 15, 2016 $30.80 $31.85 $29.66 $30.87 257 032
Nov 14, 2016 $30.00 $31.44 $28.97 $30.95 528 256
Nov 11, 2016 $27.70 $29.78 $27.26 $29.69 431 241
Nov 10, 2016 $27.82 $28.91 $27.31 $27.88 497 625
Nov 09, 2016 $23.78 $27.24 $23.44 $27.01 524 238
Nov 08, 2016 $22.14 $22.99 $21.61 $22.48 146 940
Nov 07, 2016 $21.48 $22.50 $21.15 $22.36 257 400
Nov 04, 2016 $19.97 $21.14 $19.97 $20.86 239 900
Nov 03, 2016 $21.50 $21.91 $19.54 $19.92 600 400
Nov 02, 2016 $24.09 $24.09 $21.64 $21.74 335 100
Nov 01, 2016 $23.74 $24.05 $23.00 $23.79 119 100
Oct 31, 2016 $23.83 $24.03 $23.44 $23.69 121 700
Oct 28, 2016 $23.70 $23.99 $23.02 $23.77 170 800
Oct 27, 2016 $24.86 $25.04 $23.69 $23.85 151 600
Oct 26, 2016 $24.75 $25.24 $24.26 $24.52 103 700
Oct 25, 2016 $25.42 $25.42 $24.62 $24.74 114 800
Oct 24, 2016 $26.24 $26.24 $24.98 $25.35 204 200
Oct 21, 2016 $25.19 $26.23 $23.91 $25.57 169 000
Oct 20, 2016 $24.16 $25.47 $23.88 $25.34 248 800
Oct 19, 2016 $25.58 $25.58 $24.30 $24.31 137 200
Click to get the best stock tips daily for free!

About MacroGenics

MacroGenics MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The... MGNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT